anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Diflunisal is a peripherally-acting analgesic agent with a long duration of action. Diflunisal produces significant analgesia within 1 hour and maximum analgesia within 2 to 3 hours.

Consistent with its long half-life, clinical effects of diflunisal mirror its pharmacokinetic behavior, which is the basis for recommending a loading dose when instituting therapy. Patients treated with diflunisal, on the first dose, tend to have a slower onset of pain relief when compared with drugs achieving comparable peak effects. However, diflunisal produces longer lasting responses than the comparative agents.

Comparative single dose clinical studies have established the analgesic efficacy of diflunisal at various dose levels relative to other analgesics. Analgesic effect measurements were derived from hourly evaluations by patients during eight and twelve hour postdosing observation periods. The following information may serve as a guide for prescribing diflunisal.

Diflunisal 500 mg was comparable in analgesic efficacy to aspirin 650 mg, acetaminophen 600 mg or 650 mg, and acetaminophen 650 mg with propoxyphene napsylate 100 mg. Patients treated with diflunisal had longer lasting responses than the patients treated with the comparative analgesics.

Diflunisal 1,000 mg was comparable in analgesic efficacy to acetaminophen 600 mg with codeine 60 mg. Patients treated with diflunisal had longer lasting responses than the patients who received acetaminophen with codeine.

A loading dose of 1,000 mg provides faster onset of pain relief, shorter time to peak analgesic effect, and greater peak analgesic effect than an initial 500 mg dose.

In contrast to the comparative analgesics, a significantly greater proportion of patients treated with diflunisal did not remedicate and continued to have a good analgesic effect eight to twelve hours after dosing. Seventy-five percent (75%) of patients treated with diflunisal continued to have a good analgesic response at four hours. When patients having a good analgesic response at four hours were followed, 78% of these patients continued to have a good analgesic response at eight hours and 64% at twelve hours.
At randomization participants will start with a dose of 50mg (one capsule) once a day for 2 weeks. If this dose is well tolerated and systolic BP is \>90 mm Hg and diastolic BP is \> 60 mm Hg, the dose will be increased to 100 mg (2 capsules) once a day for the remaining 46 weeks.
BACKGROUND: ATL1102 is a 2'MOE gapmer antisense oligonucleotide to the CD49d alpha subunit of VLA-4, inhibiting expression of CD49d on lymphocytes, reducing survival, activation and migration to sites of inflammation. Children with DMD have dystrophin deficient muscles susceptible to contraction induced injury, which triggers the immune system, exacerbating muscle damage. CD49d is a biomarker of disease severity in DMD, with increased numbers of high CD49d expressing T cells correlating with more severe and progressive weakess, despite corticosteroid treatment.
METHODS: This Phase 2 open label study assessed the safety, efficacy and pharmacokinetic profile of ATL1102 administered as 25 mg weekly by subcutaneous injection for 24 weeks in 9 non-ambulatory boys with DMD aged 10-18 years. The main objective was to assess safety and tolerability of ATL1102. Secondary objectives included the effect of ATL1102 on lymphocyte numbers in the blood, functional changes in upper limb function as assessed by Performance of Upper Limb test (PUL 2.0) and upper limb strength using MyoGrip and MyoPinch compared to baseline.
RESULTS: Eight out of nine participants were on a stable dose of corticosteroids. ATL1102 was generally safe and well tolerated. No serious adverse events were reported. There were no participant withdrawals from the study. The most commonly reported adverse events were injection site erythema and skin discoloration. There was no statistically significant change in lymphocyte count from baseline to week 8, 12 or 24 of dosing however, the CD3+CD49d+ T lymphocytes were statistically significantly higher at week 28 compared to week 24, four weeks past the last dose (mean change 0.40x109/L 95%CI 0.05, 0.74; p = 0.030). Functional muscle strength, as measured by the PUL2.0, EK2 and Myoset grip and pinch measures, and MRI fat fraction of the forearm muscles were stable throughout the trial period.
CONCLUSION: ATL1102, a novel antisense drug being developed for the treatment of inflammation that exacerbates muscle fibre damage in DMD, appears to be safe and well tolerated in non-ambulant boys with DMD. The apparent stabilisation observed on multiple muscle disease progression parameters assessed over the study duration support the continued development of ATL1102 for the treatment of DMD.
TRIAL REGISTRATION: Clinical Trial Registration. Australian New Zealand Clinical Trials Registry Number: ACTRN12618000970246.
The invention belongs to the technical field of neural network models, and discloses a disease association prediction method (MGAMDA) based on multi-source similarity fusion. Firstly, a plurality of similar networks of miRNA and diseases are constructed, then a plurality of information networks are fused, and features are aggregated by utilizing graph convolution. To address the problem of different levels of information being of different importance, a attention mechanism is used to assign weights. Finally, similar characteristics of the disease side and the miRNA side are obtained respectively. And combining the associated features obtained from the associated information and inputting the associated features into the multi-layer perceptron. Finally, a multi-layer perceptron is used to obtain a predicted miRNA-disease unknown association score. To verify the effectiveness of this method, the present invention performed a series of experiments using the human microRNA disease database (HMDD v 3.2). Compared with the existing method, the prediction performance is obviously improved.
Methods. We prospectively compared outcomes of subinguinal varicocelectomy for 40 patients who received 2 ml intratunical space injection of methylene blue before spermatic vein ligation with 40 controls in whom no mapping technique was adopted in the period between January 2008 and Feb. 2010, in Mansoura university hospital ward 7.After surgery, the patients were assessed at 2 weeks,6 and 12 months for varicocele recurrence, hydrocele formation, atrophy, pain or other complications with mean follow up was 15+ 7months.

Results: There were no intraoperative complications in either group. There were no adverse reactions, scrotal haematomas or atrophy. In group 1, no patient had a hydrocele at 3 months after surgery. By contrast, in group 2 (surgery alone) there were four cases of secondary hydrocele (10%; P=0.025)); no testicular hypertrophy was observed following lymphatic sparing surgery , One patient in each group had varicocele recurrence. Pregnancy was reported in 30 patients (37.5%) during a follow up period, 17 of them (42.5%) were group(1),P \>0.34. difference was not significantly different among the two groups
Disclosed herein are compounds having activity as cell penetrating peptides. In some examples, the compound can comprise a cell penetrating peptide moiety and a cargo moiety. The cargo moiety may comprise one or more detectable moieties, one or more therapeutic moieties, one or more targeting moieties, or any combination thereof. In some examples, the cell penetrating peptide moiety is cyclic. In some examples, the cell penetrating peptide moiety and cargo moiety together are cyclic. In some examples, the cell penetrating peptide moiety is cyclic, and the cargo moiety is attached to a cyclic cell penetrating peptide moiety structure. In some examples, the cargo moiety is cyclic and the cell penetrating peptide moiety is cyclic, and together they form a fused bicyclic ring system.
The present invention relates to a method of diagnosing or characterising a central nervous system disorder (CNS). The invention may also be useful in predicting the risk of developing a CNS disorder. The invention also relates to the identification of a biomarker of a CNS disorder. More specifically, the present invention contemplates the identification of an autoantibody to dopamine receptor D2R in a subject as a biomarker of a CNS disorder. The invention also relates to the treatment of a CNS disorder. Specifically, the invention contemplates the treatment of an autoimmune CNS disorder such as Sydenham's chorea, Tourette syndrome or basal ganglial encephalitis with an antagonist to antibodies to dopamine receptor D2R, such as soluble D2R.
Chimeric antigen receptor (CAR) T cells are in standard clinical use to treat relapsed or refractory hematologic malignancies, such as non-Hodgkin lymphoma, multiple myeloma and acute lymphoblastic leukemia. Owing to the rapidly progressing field of CAR T-cell therapy and the lack of generally accepted treatment guidelines, we hypothesized significant differences between European centers in prevention, diagnosis and management of short- and long-term complications. To capture the current CAR T-cell management among European Society for Blood and Marrow Transplantation (EBMT) centers and to determine the medical need and specific areas for future clinical research the EBMT Transplant Complications Working Party performed a survey among 227 EBMT CAR T-cell centers. We received complete servey answers from 106 centers (47%) addressing questions in the areas of product selection, CAR T-cell logistics, management of cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome as well as management in later phases including prolonged cytopenias. We identified common patterns in complication management, but also significant variety in clinical management of the centers in important aspects. Our results demonstrate a high medical need for treatment harmonization and future clinical research in the following areas: treatment of steroid-refractory and very severe cytokine release syndrome/neurotoxicity, treatment of cytopenia, early discharge and outpatient management, as well as immunoglobulin substitution.
Disclosed are radioactivatable compositions, preferably metal alloy compositions containing a metal having shape memory characteristics, and at least one radioactibatable isotope comprising a lanthanide series element or mixtures of lanthanide series of elements or other suitable isotope. The radioactivatable isotope is present in sufficient concentration (relative to other components of the composition) to deliver an effective radiation dose to a target tissue to achieve a specified therapeutic objective. One of the more advantageous and useful applications for this composition is the formation of medical devices for the treatment of coronary artery disease and the abatement of proliferation of cancer cells. In one of the embodiments of this invention, a radioactivatable isotope is incorporated, by isotopic beneficiated combination, with a matrix material such as nickel/titanium alloy (e.g. Nitinol metal alloys), or by isotopic beneficiated combination with a biodegradable organic naturally occurring or synthetic polymer so as to form a solid solution; and, the resultant alloy or solid solution, therafter, formed into a stent, or other suitable form, for selective, targeted delivery of therapeutic and effective amounts of low dosage radiation (e.g. beta particles) to a specific site or tissue within the body.
The children included in this arm will receive two weeks of daily care during which two daily speech therapy sessions of one hour each will be performed. This will be done between M2 and M4 of inclusion in order to avoid potential measurement bias. These sessions will be carried out by a state-qualified speech therapist employed at the CRRF of Bregille. They will guide the intensive rehabilitation of dyslexic children by focusing the exercises on their main difficulties.
PURPOSE:To obtain a plaster preparation for mucosa of oral cavity being attached to wet mucosa in oral cavity to carry out general drug administration in the oral cavity for a long period of time, comprising a specific adhesion layer. CONSTITUTION:A vinyl acetate homopolymer, a polyacrylic acid and a cellulose derivative (e.g. methyl cellulose) to be dissolved or swollen in water and in a lower alcohol as essential components are dissolved in a common solvent (e.g. lower alcohol) thereof, further mixed with a general drug and cast into a releasable liner and dried to give the aimed substance. A flexible filmy water- insoluble supporting layer is laminated to one side of the plaster preparation for mucosa of oral cavity so that the aimed substance having excellent shape retention during water absorption can be obtained. The ratio of the polyacrylic acid and the cellulose derivative is (1:9)-(9:2) by weight and the ratio of the vinyl acetate homopolymer based on the total amounts of the both the compounds is (2:8)-(8:2) by weight.
The dentifrice compn. contains enzymes, opt. vitamins, and cleaning agents, in which 20-70% of the cleaning agent consist of particles of at least 10 microns in size, and 80-30% of the cleaning agent consists of particles of at least 3 microns in size. Suitable cleaning agents are mixts of CaCO3 and Si contg. cpds, eg. SiO2, Al silicate and/or Zr silicate, and suitable enzymes are proteases, carbohydrases and dextranase. The presence of the enzymes and the cleaning agent of specified particle size increases the cleaning power of the dentrifrice, and prevents the formation of caries.
PURPOSE: Metformin, a biguanide antihyperglycemic drug, can exert various beneficial effects in addition to its glucose-lowering effect. The effects of metformin are mainly mediated by AMP-activated protein kinase (AMPK)-dependent pathway. AMPK activation interferes with the action of the mammalian target of rapamycin complex 1 (mTORC1), and blockade of mTORC1 pathway suppresses pathological retinal angiogenesis. Therefore, in this study, we examined the effects of metformin on pathological angiogenesis and mTORC1 activity in the retinas of mice with oxygen-induced retinopathy (OIR).
METHODS: OIR was induced by exposing the mice to 80% oxygen from postnatal day (P) 7 to P10. The OIR mice were treated with metformin, rapamycin (an inhibitor of mTORC1), or the vehicle from P10 to P12 or P14. The formation of neovascular tufts, revascularization in the central avascular areas, expression of vascular endothelial growth factor (VEGF) and VEGF receptor (VEGFR) 2, and phosphorylated ribosomal protein S6 (pS6), a downstream indicator of mTORC1 activity, were evaluated at P10, P13, or P15.
RESULTS: Neovascular tufts and vascular growth in the central avascular areas were observed in the retinas of P15 OIR mice. The formation of neovascular tufts, but not the revascularization in the central avascular areas, was attenuated by metformin administration from P10 to P14. Metformin had no significant inhibitory effect on the expression of VEGF and VEGFR2, but it reduced the pS6 immunoreactivity in vascular cells at the sites of angiogenesis. Rapamycin completely blocked the phosphorylation of ribosomal protein S6 and markedly reduced the formation of neovascular tufts.
CONCLUSIONS: These results suggest that metformin partially suppresses the formation of neovascular tufts on the retinal surface by blocking the mTORC1 signaling pathway. Metformin may exert beneficial effects against the progression of ocular diseases in which abnormal angiogenesis is associated with the pathogenesis.
Salivary gland squamous cell carcinomas (SG-SCCs) constitute a rare type of head and neck cancer which is linked to poor prognosis. Due to their low frequency, the molecular mechanisms responsible for their aggressiveness are poorly understood. In this work we studied the role of the phosphatase DUSP1, a negative regulator of MAPK activity, in controlling SG-SCC progression. We generated DUSP1 KO clones in A253 human cells. These clones showed a reduced ability to grow in 2D, self-renew in ECM matrices and to form tumors in immunodeficient mice. This was caused by an overactivation of the stress and apoptosis kinase JNK1/2 in DUSP1-/+ clones. Interestingly, RNAseq analysis revealed that the expression of SOX2, a well-known self-renewal gene was decreased at the mRNA and protein levels in DUSP1-/+ cells. Unexpectedly, CRISPR-KO of SOX2 did not recapitulate DUSP1-/+ phenotype, and SOX2-null cells had an enhanced ability to self-renew and to form tumors in mice. Gene expression analysis demonstrated that SOX2-null cells have a decreased squamous differentiation profile -losing TP63 expression- and an increased migratory phenotype, with an enhanced epithelial to mesenchymal transition signature. In summary, our data indicates that DUSP1 and SOX2 have opposite functions in SG-SCC, being DUSP1 necessary for tumor growth and SOX2 dispensable showing a tumor suppressor function. Our data suggest that the combined expression of SOX2 and DUSP1 could be a useful biomarker to predict progression in patients with SG-SCCs.
The invention provides a method of inducing a protective response in ceils by activating a heat shock response, via heat shock transcription factor (HSF), without stressing the ceils. The invention is based on the surprising discovery that HSF can be activated in non-stressed ceils by disrupting interaction with the repressive cognate protein, Hsc70. As described herein, non-steroida! anti-inflammatory drugs (NSAID), inciuding salicylic acid and ibuprofen, can stimuiaie HSF DNA binding, Hsp70 transcription and Hsp70 protein synthesis in non-stressed ceils. By activating HSF, the degenerative effects of certain neurodegenerative proteins such as pαiyglutamine repeat proteins (Huntington's disease) and the α-synucleiπ protein (Parkinson's disease) can be offset. The invention thus provides a method of ameliorating symptoms of neurodegenerative disease.
The invention discloses a method for establishing a transgenic cell line of target genes shRNA (short hairpin ribonucleic acid) interfering propagation of porcine reproductive and respiratory syndrome viruses. Target genes shRNA capable of preventing propagation and copy of the porcine reproductive and respiratory syndrome viruses effectively are designed, and a clonal cell line capable of preventing infection of the porcine reproductive and respiratory syndrome viruses effectively is obtained by the aid of genomes inserted into donorcells via transposons carriers. The invention further discloses an establishing method of a recombinant carrier PXL-BAC2-FRT-EGFP-NEO-shRNA. The establishing method includes designing a target gene shRNA-ORF6-6e, amplifying zsGFP and NEO fragments by PCR (polymerase chain reaction), the shRNA of the ORF6-6e is connected to a carrier pMD18-T Simple in an enzyme digestion manner, and is recovered and connection on a carrier PXL-BAC2 by enzyme digestion. The invention discloses application of the transgenic cell line. The transgenic cell line has a suppression function on the PRRSV (porcine reproductive and respiratory syndrome viruses).
<P>PROBLEM TO BE SOLVED: To provide a new antiobestic agent composed of a natural ingredient focusing attention to a plant belonging to the family Moraceae.  <P>SOLUTION: The antiobestic agent comprises an extract of root bark of a plant belonging to the family Moraceae. The antiobestic agent comprises an extract of root bark of M. alba var. multicaulis Perro. as the plant belonging to the family Moraceae.  <P>COPYRIGHT: (C)2010,JPO&INPIT
One dose only given over 1 hour. Per DSMB recommendations, this intermediate arm was stopped Jan 2010.
Participants with alcohol use disorder randomized to this group will receive their usual care but will not receive pioglitazone. Study procedures include a bronchoscopy at baseline and an additional bronchoscopy 2 to 4 weeks later.
In Group A, the maintenance dose of oral digoxin will be either 62.5mcg or 125mcg according to the pre-defined treatment schedule and uptitrated, as required, to 250mcg daily. A single loading dose of four tablets (250 or 500mcg according to target maintenance dose) will be prescribed in digoxin-naïve participants, where necessary. Recommended additional therapy in this arm includes the calcium-channel blocker diltiazem. Use of beta-blockers is explicitly discouraged but will not terminate participation in the study.
Bundle treatment after cardiac arrest. The control group utilized the same stimulation device and was subjected to a safe yet ineffective stimulation protocol for sham stimulation. The treatment lasts for 8 hours per day and the treatment course lasts for 14 days.
The present invention discloses a strain of Lactobacillus salivarius capable of inhibiting Candida albicans growth, and a separation method thereof, wherein the Latin name is Lactobacillus salivarius LI01, the Lactobacillus salivarius LI01 is preserved in the China General Microbiological Culture Collection Center, and the preservation number is CGMCC No.7045. The present invention discloses morphological characteristics of the Lactobacillus salivarius LI01, wherein the morphological characteristics comprise rod-shaped bacteria, no spore production, no motility, and positive Gram staining. The present invention discloses main components of the whole-cell fatty acid of the Lactobacillus salivarius LI01, wherein the main components comprise: about 38.48% of 16:0, about 8.29% of 18:1w9c, about 14.68% of 19:0cyclow10c/19w6, about 5.94% of 18:0, about 12.75% of 19:0cyclow10c/19w6, about 11.55% of 19:0cyclow8c, about 12.75% of 19:1w6c, and about 14.68% of 18:1w7c. The invention further discloses the whole sequence of 16S ribosomal DNA (16SrDNA) of the Lactobacillus salivarius LI01. The separation screening method of the present invention comprises three steps: carrying out enrichment culture with a MRS nutrient culture medium, adopting a Candida albicans covering layer to carry out primary screening, and adopting liquid co-culture to carry out re-screening. According to the present invention, the method is rapid and efficient, and the obtained Lactobacillus salivarius LI01 has strong Candida albicans resistance ability.
OBJECTIVE: Hypocalcemia occurs commonly among patients with acute pancreatitis (AP) in the intensive care unit (ICU). Calcium therapy could be used to correct hypocalcemia and maintain calcium levels, but its impact on the prognosis has not been demonstrated. Our study aimed to determine whether calcium therapy could benefit the multiple outcomes of AP patients with hypocalcemia.
METHODS: We extracted 807 AP patients with hypocalcemia from the Beth Israel Deaconess Medical Center (MIMIC-IV) database and performed retrospective analyses. The outcomes were in-hospital, 28 days, ICU mortality, and the length of stay (LOS) in the hospital and ICU. We performed propensity matching (PSM) and inverse probability weighting (IPTW) to balance the baseline differences and conducted multivariate regression to investigate the impact of calcium therapy.
RESULTS: A total of 620 patients (76.8%) received calcium treatment (calcium group) during hospitalization, while 187 patients (non-calcium group) did not. Patients in the calcium group did not present significant survival differences between groups before and after matching. After including covariates, calcium administration had no association with patients' in-hospital (HR: 1.03, 95% Cl: 0.47-2.27, p = .942), 28 days and ICU mortality and was significantly associated with prolonged length of stay in the hospital (effect estimate: 6.18, 95% Cl: 3.27-9.09, p < .001) and ICU (effect estimate: 1.72, 95% Cl: 0.24-3.20, p < .001). Calcium therapy could not benefit patients in subgroups with exclusive parenteral infusion, early calcium therapy (<48 h), or various degrees of hypocalcemia.
CONCLUSION: AP patients with hypocalcemia could not benefit from calcium administration, which has no association with multiple mortality and is significantly associated with prolonged LOS in the hospital and ICU.